| Dr Amanda Michelle Tompkins, OD | |
|
1717 W Cowles St, Fairbanks, AK 99701-5926 | |
| (907) 451-6682 | |
| Not Available |
| Full Name | Dr Amanda Michelle Tompkins |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 1717 W Cowles St, Fairbanks, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053743534 | NPI | - | NPPES |
| 3120 | Other | TN | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3120 (Tennessee) | Primary |
| Provider Name | Southern College Of Optometry |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851384986 PECOS PAC ID: 4587550454 Enrollment ID: O20040226000558 |
News Archive
A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).
An interview with Dr. Tim Steppe, discussing the latest advances in the CLARITY technique and his top tips for scientists using this method in their research.
Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.
Scientists look for clues about therapies and cures for life-threatening childhood illnesses in children's DNA - it seems only logical to do so. But the decision as to who should have access to DNA samples from children provides a unique ethical conundrum, says a Tel Aviv University researcher in a recent publication for the esteemed journal Science, co-authored by colleagues from The Netherlands and Canada.
› Verified 4 days ago
| Provider Name | Myeyedr Optometry Of Tennessee Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1619481587 PECOS PAC ID: 1759646995 Enrollment ID: O20180517001819 |
News Archive
A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).
An interview with Dr. Tim Steppe, discussing the latest advances in the CLARITY technique and his top tips for scientists using this method in their research.
Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.
Scientists look for clues about therapies and cures for life-threatening childhood illnesses in children's DNA - it seems only logical to do so. But the decision as to who should have access to DNA samples from children provides a unique ethical conundrum, says a Tel Aviv University researcher in a recent publication for the esteemed journal Science, co-authored by colleagues from The Netherlands and Canada.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amanda Michelle Tompkins, OD 1627 Faxon Ave, Memphis, TN 38112-4920 Ph: (901) 236-2704 | Dr Amanda Michelle Tompkins, OD 1717 W Cowles St, Fairbanks, AK 99701-5926 Ph: (907) 451-6682 |
News Archive
A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).
An interview with Dr. Tim Steppe, discussing the latest advances in the CLARITY technique and his top tips for scientists using this method in their research.
Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.
Scientists look for clues about therapies and cures for life-threatening childhood illnesses in children's DNA - it seems only logical to do so. But the decision as to who should have access to DNA samples from children provides a unique ethical conundrum, says a Tel Aviv University researcher in a recent publication for the esteemed journal Science, co-authored by colleagues from The Netherlands and Canada.
› Verified 4 days ago
Eye Clinic Of Fairbanks, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1919 Lathrop St, Suite 103, Fairbanks, AK 99701 Phone: 907-456-7760 Fax: 907-451-7916 | |
Mountain View Eye Center Optometrist Medicare: Medicare Enrolled Practice Location: 2555 Phillips Field Rd, Fairbanks, AK 99709 Phone: 907-328-2920 | |
Augusta Ann Plassmann King, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1521 Stacia St, Unit B, Fairbanks, AK 99701 Phone: 907-456-4822 | |
Anita Mullins, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 201 Old Steese Hwy Ste 2, Fairbanks, AK 99701 Phone: 907-456-4822 Fax: 907-456-4830 | |
Dr. Jeremy Fulk, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 116 Minnie St, Fairbanks, AK 99701 Phone: 907-456-7760 | |
John Charles Cobbett, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1867 Airport Way Ste 150a, Fairbanks, AK 99701 Phone: 907-452-2131 Fax: 907-452-2618 |